Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector 
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
FDA Approves Mitapivat for Anemia in Thalassemia Patients 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
Nike Stock Jumps After Apple CEO Tim Cook Buys $2.9M Worth of Shares 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
Italy Fines Apple €98.6 Million Over App Store Dominance 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
MELBOURNE, Australia and NEW YORK, Feb. 11, 2016 -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the second quarter/half year ended December 31, 2015 and provide a corporate update beginning at 5:00 pm Eastern Time on Tuesday, February 16, 2016 / 09:00 am Australian Eastern Daylight Time on Wednesday, February 17, 2016.
To access the call, dial 877-456-0438 (toll-free US), 1800-005-989 (toll-free Australia) or 262-558-6163 (outside of the US). The passcode is 49888069. The conference call will be accompanied by a slide presentation. Please log in approximately 10 minutes prior to the scheduled start time. The live webcast can be accessed by clicking here.
The archived webcast will be available in the Events and Presentations section of the Investor page on the Mesoblast website, which can be accessed by clicking here.
About Mesoblast
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) is a global leader in cell-based medicines. The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells, to establish a broad portfolio of late-stage product candidates. Mesoblast’s allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases where there are highly unmet medical needs, including cardiovascular conditions, orthopedic disorders, immunologic and inflammatory disorders and oncology/hematology conditions.
For further information, please contact: Michael Schuster Head, Investor Relations Mesoblast Limited T: 212-880-2060 E: [email protected] Julie Meldrum Global Head, Corporate Communications Mesoblast Limited T: +61 3 9639 6036 E: [email protected]
